AGAngelika Grudzińska

Angelika Grudzińska

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Angelika Grudzińska has a total of 29 co-authors. Here are the top co-authors by number of shared publications:

  • Agnieszka Anna Kaczor

    Department of Synthesis and Chemical Technology of Pharmaceutical Substances with Computer Modeling Laboratory, Faculty of Pharmacy, Medical University of Lublin, 4A Chodzki St., 20-093 Lublin, Poland

    3 shared publications
  • Tomasz Wrobel

    Department of Synthesis and Chemical Technology of Pharmaceutical Substances with Computer Modeling Laboratory, Faculty of Pharmacy, Medical University of Lublin, 4A Chodzki St., 20-093 Lublin, Poland

    3 shared publications
  • Agata Bartyzel

    Department of General and Coordination Chemistry and Crystallography, Institute of Chemical Sciences, Faculty of Chemistry, Maria Curie-Skłodowska University in Lublin, Maria Curie-Skłodowska Sq. 2, 20-031 Lublin, Poland

    1 shared publication
  • Agata Zięba

    Department of Synthesis and Chemical Technology of Pharmaceutical Substances with Computer Modeling Laboratory, Faculty of Pharmacy, Medical University of Lublin, 4A Chodzki St., PL-20093 Lublin, Poland

    1 shared publication
  • Akanksha Mudgal

    Department of Biopharmacy, Faculty of Pharmacy, Medical University of Lublin, Lublin PL-20093, Poland

    1 shared publication
  • Amit Vikram Pandey

    University of Bern, Switzerland

    1 shared publication

Latest Publications

  • Discovery and Characterization of Novel Piperidine Derivatives as Potent Cytochrome P450 17A1 Inhibitors for Prostate Cancer Therapy

    by Angelika Grudzińska, Jibira Yakubu, Chiara Vigato, Therina du Toit, Gaia Vanzetti, Radosław Zan, Donatella Boschi, Simonetta Oliaro‐Bosso, Fredrik Björkling, Flemming Steen Jørgensen, et al.

    Castration‐resistant prostate cancer relies on intratumoral androgen synthesis mediated by cytochrome P450 17A1 (CYP17A1). Treatment with the only clinically used CYP17A1 inhibitor, abiraterone, is limited by resistance and side effects, underscoring the urgent need for new CYP17A1 inhibitors with greater selectivity and improved safety profiles. In response to this challenge, we designed, synthesized, and biologically evaluated 30 novel piperidine derivatives. All compounds were initially screened in the H295R cell line to assess their inhibitory activity toward both CYP17A1 and off‐target CYP21A2. Compounds were further evaluated in cell viability assays using prostate cancer cells and a normal prostate cell line. The most potent and selective compounds were subjected to further biological studies: IC 50 determination, steroid profiling, cell migration assay, aldo–keto reductase family 1 member C3 inhibition assays, absorption, distribution, metabolism, and excretion prediction, and solubility testing. Several compounds emerged as the most active and selective leads, highlighting their potential for pharmaceutical development.


  • Open Access

    Biased signaling via serotonin 5-HT2A receptor: from structural aspects to in vitro and in vivo pharmacology

    by Michał K. Jastrzębski, Piotr Wójcik, Angelika Grudzińska, Giorgia Andreozzi, Tommaso Vetrò, Ayesha Asim, Akanksha Mudgal, Jakub Czapiński, Tomasz M. Wróbel, Damian Bartuzi, et al.


  • Open Access

    Synthesis, Structural and Behavioral Studies of Indole Derivatives D2AAK5, D2AAK6 and D2AAK7 as Serotonin 5-HT1A and 5-HT2A Receptor Ligands

    by Agnieszka A. Kaczor, Ewa Kędzierska, Tomasz M. Wróbel, Angelika Grudzińska, Angelika Pawlak, Tuomo Laitinen, Agata Bartyzel

    Serotonin receptors are involved in a number of physiological functions and regulate aggression, anxiety, appetite, cognition, learning, memory, mood, nausea, sleep, and thermoregulation. Here we report synthesis and detailed structural and behavioral studies of three indole derivatives: D2AAK5, D2AAK6, and D2AAK7 as serotonin 5-HT1A and 5-HT2A receptor ligands. X-ray studies revealed that the D2AAK5 compound crystallizes in centrosymmetric triclinic space group with one molecule in the asymmetric unit. The main interaction between the ligands and the receptors is the salt bridge between the protonatable nitrogen atom of the ligands and the conserved Asp (3.32) of the receptors. The complexes were stable in the molecular dynamic simulations. MD revealed that the studied ligands are relatively stable in their binding sites, with the exception of D2AAK7 in the serotonin 5-HT1A receptor. D2AAK7 exerts anxiolytic activity in the EPM test, while D2AAK5 has a beneficial effect on the memory processes in the PA test.


  • Open Access

    Current Approaches and Tools Used in Drug Development against Parkinson’s Disease

    by Oliwia Koszła, Piotr Stępnicki, Agata Zięba, Angelika Grudzińska, Dariusz Matosiuk, Agnieszka A. Kaczor

    Parkinson’s disease is a progressive neurodegenerative disorder characterized by the death of nerve cells in the substantia nigra of the brain. The treatment options for this disease are very limited as currently the treatment is mainly symptomatic, and the available drugs are not able to completely stop the progression of the disease but only to slow it down. There is still a need to search for new compounds with the most optimal pharmacological profile that would stop the rapidly progressing disease. An increasing understanding of Parkinson’s pathogenesis and the discovery of new molecular targets pave the way to develop new therapeutic agents. The use and selection of appropriate cell and animal models that better reflect pathogenic changes in the brain is a key aspect of the research. In addition, computer-assisted drug design methods are a promising approach to developing effective compounds with potential therapeutic effects. In light of the above, in this review, we present current approaches for developing new drugs for Parkinson’s disease.